Fascia Iliaca Compartment Block For Analgesia After Total Hip Arthroplasty
| Status: | Completed |
|---|---|
| Conditions: | Psychiatric |
| Therapuetic Areas: | Psychiatry / Psychology |
| Healthy: | No |
| Age Range: | 18 - 75 |
| Updated: | 12/30/2016 |
| Start Date: | October 2010 |
| End Date: | August 2011 |
Fascia Iliaca Compartment Block For Analgesia After Total Hip Arthroplasty; A Randomized Double Blind, Placebo-Controlled Trial
Introduction Fascia Iliaca compartment block (FICB) is commonly used to treat pain in
patients after total hip arthroplasty (THA) despite the lack of RCTs to evaluate the
efficacy of FICB for this indication. Therefore the objective of this study was to assess
the analgesic benefit of FICB for post-operative pain management in THA.
Methods After IRB approval and informed consent, patients having THA at our center in the
period 2010-2011 were recruited. Eligible patients were adults, ASA physical status I-III,
and BMI <30) with no contraindication to study procedures. In the PACU, all patients
received morphine sulfate IVPCA; patients reporting pain > 3 on the NRS-11 despite IVPCA
were randomized by the method of sealed envelopes to receive US guided injections of 30ml
0.5% ropivacaine (FICB) or 30ml 0.9% NaCl (sham block, SB) beneath the fascia iliaca.
The primary outcome variable was opioid analgesic consumption during the first 24 h
postoperatively. Secondary outcome measures were pain intensity (NRS-11) and extent of
sensory blockade.
patients after total hip arthroplasty (THA) despite the lack of RCTs to evaluate the
efficacy of FICB for this indication. Therefore the objective of this study was to assess
the analgesic benefit of FICB for post-operative pain management in THA.
Methods After IRB approval and informed consent, patients having THA at our center in the
period 2010-2011 were recruited. Eligible patients were adults, ASA physical status I-III,
and BMI <30) with no contraindication to study procedures. In the PACU, all patients
received morphine sulfate IVPCA; patients reporting pain > 3 on the NRS-11 despite IVPCA
were randomized by the method of sealed envelopes to receive US guided injections of 30ml
0.5% ropivacaine (FICB) or 30ml 0.9% NaCl (sham block, SB) beneath the fascia iliaca.
The primary outcome variable was opioid analgesic consumption during the first 24 h
postoperatively. Secondary outcome measures were pain intensity (NRS-11) and extent of
sensory blockade.
Introduction Fascia Iliaca compartment block (FICB) is commonly used to treat pain in
patients after total hip arthroplasty (THA) despite the lack of RCTs to evaluate the
efficacy of FICB for this indication. Therefore the objective of this randomized,
prospective trial was to assess the analgesic benefit of FICB for post-operative pain
management in THA. Our hypothesis was that FICB would confer an analgesic benefit for
patients after THA.
Methods After IRB approval and informed consent, patients having THA at our center in the
period 2010-2011 were recruited in the morning of their surgery. Eligible patients were
adults, ASA physical status I-III, and BMI <30) with no contraindication to study
procedures. In the PACU, all patients received morphine sulfate IVPCA; patients reporting
pain > 3 on the NRS-11 despite IVPCA were randomized by the method of sealed envelopes to
receive US guided injections of 30ml 0.5% ropivacaine (FICB) or 30ml 0.9% NaCl (sham block,
SB) beneath the fascia iliaca.
The primary outcome variable was opioid analgesic consumption during the first 24 h
postoperatively. Secondary outcome measures were pain intensity (NRS-11) and extent of
sensory blockade.
patients after total hip arthroplasty (THA) despite the lack of RCTs to evaluate the
efficacy of FICB for this indication. Therefore the objective of this randomized,
prospective trial was to assess the analgesic benefit of FICB for post-operative pain
management in THA. Our hypothesis was that FICB would confer an analgesic benefit for
patients after THA.
Methods After IRB approval and informed consent, patients having THA at our center in the
period 2010-2011 were recruited in the morning of their surgery. Eligible patients were
adults, ASA physical status I-III, and BMI <30) with no contraindication to study
procedures. In the PACU, all patients received morphine sulfate IVPCA; patients reporting
pain > 3 on the NRS-11 despite IVPCA were randomized by the method of sealed envelopes to
receive US guided injections of 30ml 0.5% ropivacaine (FICB) or 30ml 0.9% NaCl (sham block,
SB) beneath the fascia iliaca.
The primary outcome variable was opioid analgesic consumption during the first 24 h
postoperatively. Secondary outcome measures were pain intensity (NRS-11) and extent of
sensory blockade.
Inclusion Criteria:
- Adults
- ASA physical status I-III
- BMI<30
- No contraindications to study procedures
Exclusion Criteria:
- Pediatric patients
- ASA physical status IV
- BMI>30
- Contraindications to study procedures
- Hypersensitivity to local anesthetics
We found this trial at
1
site
Click here to add this to my saved trials
